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Impact of Including Peritumoral 
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We assessed the impact of including peritumoral edema in radiotherapy volumes on recurrence patterns 
among glioblastoma multiforme (GBM) patients treated with standard chemoradiotherapy (CRT). We 
analyzed 167 patients with histologically confirmed GBM who received temozolomide (TMZ)-based 
CRT between May 2006 and November 2012. The study cohort was divided into edema (+) (n = 130) 
and edema (−) (n = 37) groups, according to whether the entire peritumoral edema was included. At 
a median follow-up of 20 months (range, 2–99 months), 118 patients (71%) experienced progression/
recurrence (infield: 69%; marginal: 26%; outfield: 16%; CSF seeding: 12%). The median overall survival 
and progression-free survival were 20 months and 15 months, respectively. The marginal failure rate 
was significantly greater in the edema (−) group (37% vs. 22%, p = 0.050). Among 33 patients who had 
a favorable prognosis (total resection and MGMT-methylation), the difference in the marginal failure 
rates was increased (40% vs. 14%, p = 0.138). Meanwhile, treatment of edema did not significantly 
increase the incidence of pseudoprogression/radiation necrosis (edema (−) 49% vs. (+) 37%, p = 0.253). 
Inclusion of peritumoral edema in the radiotherapy volume can reduce marginal failures following TMZ-
based CRT without increasing pseudoprogression/radiation necrosis.
Currently, standard treatment for glioblastoma (GBM) is surgical resection followed by chemoradiother-
apy with temozolomide (TMZ)1,2. However, the optimal radiation treatment volume is still a matter of debate. 
Radiotherapy fields and treatment volumes have evolved since the 1970s when whole-brain radiotherapy was 
considered the standard therapy3. Several studies demonstrated that disease progression was noted even within 
the region receiving the highest radiation dose among patients with a total brain dose of 60 Gy. As a result, a 
smaller volume than whole-brain has been proposed to reduce toxicity4,5. Multiple autopsy series and clinical 
studies demonstrated that tumor progression is predominantly within 2–3 cm of the primary tumor bed6,7, and a 
smaller radiotherapy volume limited to the tumor bed does not show any apparent impact on survival or change 
the failure pattern in the radiotherapy-alone era6–10. These findings led to the adaptation of 2–3 cm radiation mar-
gins by many groups, including the European Organization for Research and Treatment of Cancer (EORTC)1,2. 
On the other hand, other groups, including the Radiation Therapy Oncology Group (RTOG) still used 2 cm 
margins beyond the extent of the peritumoral edema11. This was based on post-mortem studies confirming tumor 
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cells within the peritumoral edema12, and a margin of 3 cm beyond the edema was proposed as an optimal margin 
to ensure complete coverage of all tumor cells13.
In the era of concurrent chemoradiotherapy with TMZ, many studies have reported that local recurrence is still 
a major failure pattern in limited-margin radiotherapy. Recently, several studies reported improved local control 
but higher rates of distant failures in patients with favorable prognostic factors including O6-methylguanine-DNA 
methyltransferase (MGMT) promoter methylation or extensive surgical resection14–18. However, there is no 
report so far concerning the relationship between radiotherapy volume and these prognostic factors.
In our institution, most patients were treated with small-field radiotherapy until 2008, as we followed the 
radiotherapy guidelines of RTOG 98–0319. We reported favorable outcomes with our standard chemoradiother-
apy20. However, with an increasing rate of gross total/subtotal resection and an empirical experience of frequent 
out-field recurrence without in-field recurrence, we have changed to larger-field radiotherapy including the per-
itumoral edema.
We assessed the impact of including the peritumoral edema in radiotherapy volumes on recurrence patterns 
according to extent of surgical resection and MGMT promoter methylation status among GBM patients treated 
with the standard chemoradiotherapy in a single institution cohort.
Methods
Patients. Between May 2006 and November 2012, 179 consecutive patients with histologically confirmed 
GBM were treated with TMZ-based adjuvant chemoradiotherapy. We selected 167 patients for our analysis, 
excluding five patients who were initially diagnosed with leptomeningeal seeding and seven patients who received 
whole-brain radiotherapy for gliomatosis cerebri or extensive disease. MGMT gene promoter methylation status 
was determined for 145 patients (87%) using a methylation-specific polymerase chain reaction as preciously 
Characteristics
All patients (N = 167) Edema (+) RT (N = 130) Edema (−) RT (N = 37)
p value*No. (%) No. (%) No. (%)
Age Median 59 (range, 19–79)
 < 60-year 82 (52) 66 (51) 21 (57) 0.52
 ≥ 60-year 80 (48) 64 (49) 16 (43)
Sex
 M 85 (51) 65 (50) 20 (54) 0.66
 F 82 (49) 65 (50) 17 (46)
KPS Median 80 (range, 30–100)
 < 80 95 (57) 56 (43) 16 (43) 0.99
 ≥ 80 72 (43) 74 (57) 21 (57)
Multiplicity
 Yes 28 (17) 24 (19) 4 (11) 0.26
 No 138 (83) 106 (81) 33 (89)
Gliomatosis
 Yes 12 (7) 10 (8) 2 (5) 0.64
 No 155 (93) 120 (92) 35 (95)
Ventricle involvement
 Yes 39 (23) 28 (22) 11 (30) 0.30
 No 128 (77) 102 (79) 26 (70)
MGMT methylation
 Methylation 59 (35) 43 (33) 16 (43) 0.40
 Unmethylation 86 (52) 68 (52) 18 (49)
 Unknown 22 (13) 19 (15) 3 (8)
Surgical extent
 GTR 78 (47) 57 (44) 21 (57) 0.70
 STR 48 (29) 35 (27) 13 (35)
 PR 24 (14) 22 (17) 2 (5)
 Biopsy 17 (10) 16 (12) 1 (3)
RT dose Median 60 (range, 54–70)
 < 70 Gy 153 (92) 126 (97) 27 (73) < 0.0001
 ≥ 70 Gy 14 (8) 4 (3) 10 (27)
Table 1. Patient characteristics. Abbreviations: KPS = Karnofsky performance status scale; MGMT = O6-
methyl guanine-DNA methyltransferase; GTR = gross total resection; STR = subtotal resection; PR = partial 
resection; MRI = magnetic resonance imaging; RT = radiotherapy. *p value in edema (+ ) RT group vs. edema 
(− ) RT group.
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described20 (Table 1). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, 
as revised in 1983, and was approved by Institutional review board (IRB) of Yonsei University Health System. The 
patient records/information was anonymized and de-identified prior to analysis, and informed consent was not 
obtained from each participants.
Treatment. Surgical tumor resection was performed in 150 patients (90%), and 17 patients (10%) under-
went stereotactic biopsy. The extent of surgical resection (EOR) in each patient was evaluated using operative 
findings and postoperative brain magnetic resonance imaging (MRI) reviewed by the radiologist, neurosurgeon, 
and radiation oncologist. A postoperative MRI was obtained within 48 hours after surgery for 96% (n = 135) 
patients. EOR was categorized as gross total resection (GTR), subtotal resection (STR), and partial resection (PR). 
Resection of a gross tumor by 90% or more was defined as STR, and less than 90% defined as PR. GTR and STR 
were achieved in 47 and 29% of all patients, respectively.
All of the patients received concurrent chemoradiotherapy with TMZ (75 mg/m2 of body-surface area per 
day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150–
200 mg/m2 for 5 days during each 28-day cycle). Radiotherapy was initiated 10 to 43 days (median, 19 days) after 
surgery.
Large-field and small-field radiotherapy was used in 108 and 59 patients, respectively. Gross tumor volumes 
(GTVs) in both fields consisted of the resection cavity and any residual contrast-enhancing tumor on the imme-
diate postoperative MRI. When we delineate GTV, we added 0.5–1 cm margin to compensate irregularity and 
uncertainty. The clinical target volume (CTV) in the large-field deliberately included peritumoral edema, which 
is detected on T2-weighted fluid-attenuated inversion recovery (Flair) postoperative MRI images (peritumoral 
edema + 1–1.5 cm margin). The CTV in the small-field was delineated by adding a 1.5 cm margin to the GTV, 
regardless of the presence of peritumoral edema. A 3 mm-margin for setup uncertainty was applied to create the 
planning target volume (PTV) in the 3-dimensional conformal radiotherapy (3D-CRT) plan. No PTV margin 
was added in the intensity-modulated radiation therapy (IMRT) plan.
One hundred fifty-one patients (90%) were treated with 3D-CRT, and 16 patients (10%) were treated with 
IMRT. The Pinnacle planning system (Philips Medical Systems, Cleveland, OH) was used for 3D-CRT plans, 
and the Tomotherapy Hi-Art System (TomoTherapy, Madison, WI) for IMRT plans. The prescribed dose in 
3D-CRT was 46 Gy in 23 fractions to the CTV and a boost to the GTV of 14 Gy in seven fractions. In IMRT plans, 
60 Gy in 30 fractions was prescribed to GTV and 51 Gy in 30 fractions to CTV using a simultaneous-integrated 
boost (SIB) technique. The median total radiation dose was 60 Gy (range 54–72.5 Gy). Fourteen patients (8%) 
received ≥ 70 Gy, and four patients (2%) received < 60 Gy (range, 54–58.6 Gy).
In our dosimetric analysis comparing target volume and extent of peritumoral edema, we found 22 patients 
(37%) in the small-field group actually received radiotherapy including the peritumoral edema in the CTV unin-
tentionally due to the initially narrow range of edema. Thus, the entire study cohort was divided into two groups, 
edema (+ ) (n = 130) and edema (− ) (n = 37), according to whether or not the entire peritumoral edema was 
included within the CTV. Patient characteristics between the edema (+ ) and edema (− ) group were compared 
(Table 1).
Follow-up and outcome analysis. Survival rates and failure pattern according to the radiotherapy target 
volume were analyzed. All patients were followed-up until death or time of analysis. The median follow-up dura-
tion was 20 months (range, 2–99 months). Follow-up MRI was performed 4 weeks after the end of concurrent 
chemoradiotherapy, 23 days after the end of the 3rd and 6th TMZ cycles, every 6 months for the first 2 years after 
the end of Stupp’s protocol, and annually thereafter. Disease progression was diagnosed by radiologic findings 
as well as neurologic and clinical findings using the Response Assessment in Neuro-Oncology (RANO) criteria.
To determine the location of treatment failures, simulation computed tomography (CT) images containing 
isodose volumes from radiotherapy planning were co-registered with the MRI that detected treatment failure 
using MIM software version 6.0.6 (MIM Software Inc., Cleveland, OH)21. Disease progression was categorized as 
followings according to location of T1 Gd-enhancing recurrent tumor: infield GTV (within the 60 Gy volume), 
infield CTV (outside the 60 Gy volume but within the 46 Gy volume), marginal failure (within 2 cm from the 
46 Gy volume), outfield failure (all outside the CTV), and cerebrospinal fluid (CSF) seeding. Fig. 1 illustrates 
examples with isodose curves from the radiation treatment plan overlaid onto the MRI at the time of failure.
Patients with early enhancement within 3–5 months from the initiation of adjuvant therapies with a 
self-limited course and eventual resolution both clinically and radiographically were regarded as pseudoprogres-
sion22. Radiation necrosis (RN) was confirmed by operation or serial MRI images that showed improvement of a 
newly developed contrast enhanced lesion.
Statistical analysis. Overall survival (OS) was estimated from the date of surgery to the date of death for 
any cause or of the last follow-up. Progression-free survival (PFS) was measured from the date of surgery to the 
date of recurrence or progression or to the last follow-up date for patients who did not experience these events. 
Survival differences were estimated using the log-rank test. Chi-squared analysis was performed to determine 
differences in patterns of failure between subgroups. SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) was used 
and p-values < 0.05 were considered statistically significant.
Results
Survival and prognostic factor analysis. Disease progression was noted in 118 patients (71%) at a 
median 11 months (range, 1–68 months) from the date of surgery. A total of 133 deaths occurred among all 
patients, with 34 patients remaining alive until last follow-up (OS: median 36 months (range, 24–99 months). 
Twenty-six patients without disease progression on last follow-up images died later after aggravation of existing 
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neurologic symptoms or pneumonia. In all patients, the median OS was 20 months, and 2- and 3-year OS rates 
were 43 and 27%, respectively. The median PFS was 15 months, and 2- and 3-year PFS rates were 35 and 23%, 
respectively.
In multivariate analysis, age (< 60), EOR (GTR vs. non-GTR), and MGMT-methylation were independent 
prognostic factors for OS (p = 0.032, 0.004, 0.010, respectively), and EOR and MGMT-methylation were inde-
pendent prognostic factors for PFS (p = 0.002, 0.012, respectively) (Table 2).
Patterns of failure. Figure 2(a) illustrates the patterns of failure observed in all patient cohorts. The most 
common pattern was infield failure (82 patients, 69% of all failures). Almost all infield failures occurred within the 
GTV. GTV-only failures were noted in 61 patients (52%), GTV and CTV failures in seven (6%), and CTV-only 
failures in two (2%). Marginal failures were observed in 30 patients (26%) and outfield failures in 19 (16%). CSF 
seeding was identified in 14 patients (12%). Five patients were diagnosed with failures as CSF seeding only. The 
overall median times to infield, marginal, and outfield failure were 9 months (range, 1–68), 13 months (range, 
2–56), and 14 months (range, 5–28), respectively.
Relationship between radiotherapy volume and failure pattern. In the edema (− ) group (n = 37), 
failures were identified in 30 patients (81%) (infield 53% > marginal 37% > outfield 10%). In the edema (+ ) group 
(n = 130), failures were identified in 88 patients (68%), and the rate of infield failures was higher and the rate of 
marginal failures was lower than the edema (− ) group (infield 76% > marginal 22% > outfield 18%) (Table 3, 
Fig. 2(b),(c)). In chi-squared analysis, the marginal failure rate was significantly greater in the edema (− ) group 
than the edema (+ ) group (37% vs. 22%, p = 0.050). The significance of peritumoral edema inclusion on marginal 
failure was maintained on multivariate analysis (odds ratio [OR], 0.277 [95% CI, 0.108–0.709]; p = 0.007) after 
adjusting for all potential confounding factors including radiation dose > 70 Gy, GTR, and MGMT methylation 
using logistic regression analysis. No significant difference was observed between the edema (− ) and edema (+ ) 
groups in terms of infield GTV (47% vs. 61%, p = 0.288), infield CTV (7% vs. 8%, p = 0.138), and outfield-failures 
(10% vs. 18%, p = 0.572).
Figure 1. Examples of (a) infield GTV, (b) infield CTV, (c) marginal, and (d) outfield failures. Red and green 
lines represent isodose lines of 60-Gy and 46-Gy irradiation, respectively. Sky blue line represent an isodose line 
of 30-Gy and purple line represent an isodose line of 12 Gy.
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Pattern of failure
Failure No. (%) Infield Marginal Outfield CSF seeding only
No. (%*)
All patients (n = 167) 118 (71%) 82 (69%) 30 (26%) 19 (16%) 5 (4%)
Subgroups (according to prognostic factors)
 GTR (n = 78) 50 (64%) 34 (68%) 12 (24%) 13 (28%) 3 (6%)
 MGMT methylation (n = 59) 37 (63%) 22 (59%) 10 (27%) 10 (27%) 4 (11%)
 GTR + MGMT methylation (n = 33) 17 (52%) 8 (47%) 5 (29%) 6 (36%) 1 (6%)
 GTR + MGMT methylation + Age < 60-year (n = 16) 7 (44%) 3 (43%) 2 (28%) 4 (57%) 0
Subgroups (according to RT target volume)
 Edema (+ ) RT (n = 130) 88 (68%) 66 (76%) 19 (22%) 16 (18%) 3 (3%)
 Edema (− ) RT (n = 37) 30 (81%) 16 (53%) 11 (37%) 3 (10%) 2 (7%)
Subgroups (according to prognostic factors & RT target volume)
 GTR & edema (+ ) RT (n = 57) 33 (58%) 26 (46%) 6 (11%) 10 (18%) 3 (9%)
 GTR & edema (− ) RT (n = 21) 17 (81%) 8 (38%) 6 (29%) 3 (14%) 4 (19%)
 MGMT methylation & edema (+ ) RT (n = 43) 27 (63%) 19 (70%) 6 (22%) 7 (26%) 3 (11%)
 MGMT methylation & edema (− ) RT (n = 16) 10 (63%) 3 (30%) 4 (40%) 3 (30%) 1 (10%)
 GTR + MGMT methylation & edema (+ ) RT (n = 19) 7 (37%) 5 (71%) 1 (14%) 3 (43%) 0
 GTR + MGMT methylation & edema (− ) RT (n = 14) 10 (71%) 3 (30%) 4 (40%) 3 (30%) 1 (10%)
Table 3. Patterns of failure in each patient subgroup. Abbreviations: GTR = gross total resection; 
MGMT = O6-methyl-guanine-DNA methyltransferase; RT = radiotherapy; CSF = cerebrospinal fluid. *% in all 








p value p value p value p value
Age 0.004 0.032 0.719 0.862
 < 60-year 50 35
 ≥ 60-year 34 36
Surgery < 0.001 0.004 < 0.001 0.002
 GTR 57 45
 < GTR 31 27
RT dose 0.766 0.479
 < 70 Gy 43 36
 ≥ 70 Gy 48 29
KPS 0.009 0.364 0.217 0.701
 < 80 33 33
 ≥ 80 51 38
Multiplicity 0.004 0.075 0.040 0.113
 Yes 27 22
 No 47 38
Ventricle involvement 0.021 0.363 0.103 0.507
 Yes 33 23
 No 47 39
MGMT methylation 0.002 0.010 0.005 0.012
 Methylation 61 53
 Unmethylation 34 22
 Unknown 32 45
Edema inclusion 0.535 0.657
 Yes 42 37
 No 49 29
Pseudoprogression/RN 0.090 0.755
 Yes 58 38
 No 34 33
Table 2.  Univariate and multivariate analysis for patient survival. Abbreviations: GTR = gross total 
resection; RT = radiotherapy; KPS = Karnofsky performance status scale; MGMT = O6-methylguanine-DNA 
methyltransferase; RN = radiation necrosis; OS = overall survival; PFS = progression-free survival; HR = hazard 
ratio; CI = confidence interval.
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There was no significant difference in PFS and OS or timing of failure between the two subgroups. The 
two-year PFS and OS rates were 37 and 41% for the edema (+ ) group and 29 and 49% for the edema (− ) group 
(p = 0.827, 0.392, respectively) (Fig. 3(a),(b)).
Relationship between prognostic factors and failure pattern. Failure patterns were analyzed among 
subgroups of patients with favorable prognostic factors. In the GTR subgroup (n = 78), failures were identified 
in 50 patients (64%) (infield 68% > outfield 28% > marginal 24%). In the GTR + MGMT-methylation subgroup 
(n = 33), failures were identified in 17 patients (52%) (infield 47% > outfield 36% > marginal 29%). Although 
infield failure was the dominant pattern of failure in most subgroups, it was demonstrated that both marginal 
and outfield failures tended to increase and infield failures tended to decrease with the addition of a favorable 
prognostic factor (Table 3).
Failure patterns according to the radiotherapy volume in the favorable prognostic group. 
Among 78 patients with GTR, total failure rate was decreased (58% vs. 81%, p = 0.060) and less marginal 
failures were noted (11% vs. 29%, p = 0.075) in the edema (+ ) group. Among 33 patients with GTR and 
MGMT-methylation, failure rate was further decreased (71% vs. 37% for edema (− ) vs. (+ ) group, p = 0.049). 
The benefit of treating peritumoral edema on reducing marginal failure was more apparent (40% vs. 14% for 
edema (− ) vs. (+ ) groups, p = 0.138) in this highly favorable prognostic group in comparison with that in the 
whole patient cohort. In particular, there was no marginal failure without infield failure when peritumoral edema 
was treated in this favorable group (Table 3, Fig. 2(d),(e)). However, there was no significant difference in sur-
vival outcome. The median PFS rates were 68 months in the edema (+ ) group and 19 months in the edema (− ) 
group. The 2-year PFS rates were 82% for the edema (+ ) group and 47% for the edema (− ) group (p = 0.303). The 
median OS rates were 45 months in the edema (+ ) group and 32 months in the edema (− ) group. The 2-year OS 
rates were 84% for the edema (+ ) group and 71% for the edema (− ) group (p = 0.433) (Fig. 3(c),(d)).
Figure 2. Patterns of failures (a) in all patients (n = 167), (b) in the edema (− ) group (n = 37), and (c) in 
the edema (+ ) group (n = 130); Patterns of failures among patients with favorable prognosis (GTR, MGMT-
methylation) (d) with edema (− ) RT (n = 14) or (e) with edema (+ ) RT (n = 19).
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Toxicity. Among 167 patients, pseudoprogression/RNs occurred in 66 patients (40%). Among patients with 
failure (n = 118), pseudoprogression/RNs occurred in 53 patients (45%). Treatment of peritumoral edema did 
not significantly increase the incidence of pseudoprogression/RN (edema (‒ ) vs. (+ ): 49% vs. 37%, p = 0.253). 
Radiation dose > 60 Gy was the only independent factor on multivariate analysis (OR, 2.7 [95% CI, 1.250–5.840]; 
p = 0.011).
Discussion
Regarding the optimal radiotherapy volume, several retrospective studies suggested that a limited margin did 
not alter the failure patterns. In M.D Anderson Cancer Center, 48 patients were treated with a small field not 
intentionally including peritumoral edema. Recurrence patterns were compared between treatment planning 
parameters and newly created theoretical radiotherapy plans to include peritumoral edemas. Patterns of failure 
were identical between the two sets of plans with dominant central recurrence. It should be noted, however, only 
one-third (16/48) underwent GTR and 17 patients (35%) received adjuvant chemotherapy in this study23. A 
study from Italy also showed similar results supporting small field; however, while central recurrence was dom-
inant (79/105, 75%) in 105 patients who received a current standard chemoradiation regimen with a small field, 
they observed higher rates of outfield failures in patients with MGMT methylation14. One UK study24 analyzed 
patterns of failure after TMZ-based chemoradiation with a small radiation field, and central relapses within the 
2 cm remained predominant (77%). They concluded that a 2 cm margin from the primary enhancing mass is an 
appropriate technique. These results contrast with those of Gaspar et al.25, who found that smaller boost fields 
increased marginal tumor recurrences.
These pattern-of-failure studies, however, included patients who were treated with radiotherapy alone, radi-
otherapy with non-TMZ chemotherapy, and uncompleted TMZ chemotherapy, and only 9–30% of the patients 
received total tumor resection. Furthermore, no study included molecular data such as MGMT methylation sta-
tus and stratified patients accordingly. Recent multicenter trials (RTOG 052526 and CENTRIC EORTC 26071-
22072)27 permitted both RTOG and EORTC protocols and showed no significant benefit of treating peritumoral 
edema in PFS and OS. However, detailed reports on the pattern of failure are lacking. Brandes et al.15 were the first 
to evaluate patterns of recurrences in the TMZ-based chemoradiation era. They observed that the failure pattern 
had shifted from local/marginal to distant recurrences outside the radiotherapy field, occurring in approximately 
20% of cases. Furthermore, distant recurrences occurred significantly later than local recurrences (14.9 vs. 9.2 
months, p = 0.02). Milano et al.28 also reported that the risk of central recurrence persists over time, but marginal, 
distant, and new infield recurrences tend to occur later in patients with longer survival times.
Figure 3. PFS and OS among all patients ((a) and (b)) and PFS and OS in patients with favorable prognosis 
(GTR, MGMT-methylation) ((c) and (d)) are compared according to inclusion of peritumoral edema in the 
radiotherapy target volume.
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Regarding molecular prognostic marker status, 68–91% of patients without MGMT promoter methylation 
had local recurrence and 5.4–32% had distant recurrence, while fewer patients (58–65%) with MGMT promoter 
methylation had local recurrence, but more (31–42%) had distant recurrence14–17. The extent of surgical resection 
is one of the most important prognostic factors and could affect recurrence patterns. In the era of chemoradiation 
with TMZ, the local control rate can be improved with total tumor resection, and outfield recurrences can occur 
more frequently than before due to prolonged survival with local control. When small-field radiotherapy was 
applied to patients with GTR or STR, outfield failure increased up to 21.5%15. On the other hand, the patients with 
residual tumor after surgery showed significantly higher rates of local recurrence and lower rates of distant recur-
rence in comparison with the patients whose tumors were totally removed24,29,30. Although the characteristics of 
the patients were different in reported series and the definition of recurrence is not univocal, it has been suggested 
that favorable factors, including MGMT promoter methylation and GTR, prolonged PFS with decreased local 
recurrences and relatively increased distant recurrences.
All of our study patients received standard TMZ-based chemoradiotherapy, and a large portion of patients 
received extensive surgical resection (GTR 47%, STR 29%). Furthermore, MGMT methylation status was exam-
ined in most patients (87%). We also examined radiotherapy target volumes in all patients and determined 
whether or not actual inclusion of peritumoral edema influenced the recurrence pattern. Even though infield fail-
ure was the dominant pattern of failure in our study, the rates of marginal or outfield failure tended to increase in 
the patients with favorable prognostic factors (GTR and MGMT-methylation). We also suggest that inclusion of 
peritumoral edema in the radiotherapy target volume may reduce marginal failures without increasing radiation 
necrosis, especially in patients with totally resected and/or methylated MGMT.
Several limitations exist in our study. The relatively small number of marginal failures makes it difficult to find 
statistical significance when patients are subdivided according to prognostic factors and radiotherapy target vol-
umes. Furthermore, the retrospective nature of our study makes it difficult to compare neurocognitive outcomes 
in relation to treatment volumes. A multi-institutional prospective study will be valuable in overcoming these 
limitations.
In conclusion, our study suggests that inclusion of peritumoral edema in the radiotherapy target volume may 
further reduce marginal failures without increasing toxicity, especially when favorable prognosis is expected by 
GTR and/or MGMT methylation. A prospective study with larger number of patients is needed to confirm our 
observations.
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